Vaccine trial aims to stop aggressive breast Cancer's return
NCT ID NCT03384914
Summary
This study is testing two different vaccines designed to prevent breast cancer from returning in patients with HER2-positive disease. It focuses on people who still had cancer cells remaining after completing their initial chemotherapy and targeted therapy. Researchers will monitor participants for two years to see if the vaccines safely boost the immune system and delay or prevent cancer recurrence.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Emory - Winship Cancer Institute
Atlanta, Georgia, 30322, United States
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
-
Indiana University - Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, 46202, United States
-
Ohio State University - Arthur G James Cancer Hospital & Richard J Solove Research Institute
Columbus, Ohio, 43210, United States
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
University of Washington, Fred Hutchinson Cancer Research Center
Seattle, Washington, 98109, United States
Conditions
Explore the condition pages connected to this study.